Compare General Dynamics Corporation (GD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Sanofi SA — how do they compare? General Dynamics Corporation trades at $366.89 (market cap $98.88B), while Sanofi SA trades at $43.75 (market cap $103.94B). The key difference: General Dynamics Corporation and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.54%). Which is the better fit depends on your goals.
| GD | SNY | |
|---|---|---|
Market Cap | $98.88B | $103.94B |
Sector | Industrials | Health |
52-Week High | $376.88 | $52.34 |
52-Week Low | $297.05 | $41.33 |
Enterprise Value | $105.06B | $120.43B |
Dividend Yield | 1.74% | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $369.5, down 0.88% on the day, with a bullish technical signal and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $4.10 surpassing the $3.67 expectation. Revenue growth is robust, reaching $52.55B in 2025, while net income margin improved to 8.07%. The stock is supported by a substantial $130.8 billion backlog and a consistent dividend, with the next payment of $1.59 scheduled for August 7, 2026.
The outlook for GD is positive, driven by strong defense spending tailwinds, naval contract dominance, and consistent earnings beats. Investment opportunities include exposure to growing submarine and C5ISR markets. Key risks involve execution on massive backlogs, potential defense budget volatility, and valuation metrics (P/E of 23.01) that are above some industry peers, requiring sustained growth to justify.
Sanofi (SNY) trades at $43.18, down 1.86% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 71.92% gross margins and 15.95% net income margin, supported by recent FDA approvals for Sarclisa and other pipeline developments. Cash flow remains positive at $49 million for 2025, though net cash flow has declined from previous years.
Investment outlook is mixed with analyst consensus leaning neutral (44% buy, 52% hold) amid regulatory scrutiny from EU antitrust probes. Key opportunities include Dupixent's growth and new drug approvals, while risks involve competition and patent expirations. The stock trades at reasonable valuations with P/E of 19.37 and P/B of 1.26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
